Mabion

Executive Summary

Mabion is a Poland-based Contract Development and Manufacturing Organization (CDMO) specializing in end-to-end biologics services for antibodies and biosimilars. Founded in 2007, the company offers comprehensive capabilities from cell line development and drug substance manufacturing to fill-and-finish, positioning itself as a strategic partner with a collaborative, innovation-driven approach. Mabion's focus on deep client engagement and process optimization enables it to serve a growing pipeline of biosimilar and novel antibody programs. The company operates in the rapidly expanding CDMO market, driven by increasing demand for outsourced biologics manufacturing, particularly for biosimilars in emerging markets. Mabion's location in Poland offers cost advantages and access to European Union talent and regulatory frameworks. While the company has not disclosed recent financials or fundraising rounds, its established presence and service portfolio indicate a steady operational base. Key strengths include integrated services, experienced management, and a strategic location. However, as a private company, Mabion faces challenges in scaling capacity and competing against larger global CDMOs. Future growth will depend on winning new contracts, expanding manufacturing capabilities, and potentially pursuing strategic partnerships or funding to accelerate expansion.

Upcoming Catalysts (preview)

• Q4 2026Announcement of major biosimilar manufacturing contract60% success
• Q2 2027Completion of capacity expansion at Łódź facility75% success
• TBDStrategic partnership or minority investment from a larger CDMO40% success